<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03423381</url>
  </required_header>
  <id_info>
    <org_study_id>2017-03575</org_study_id>
    <nct_id>NCT03423381</nct_id>
  </id_info>
  <brief_title>Dietary Fibre and Metabolic Benefits</brief_title>
  <official_title>Validation of a New Antidiabetic Food Concept Based on Modulation of the Gut Microbiota</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vinnova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ã–ste Venture AB</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lund University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the project is to study the connection between bacterial fermentation in the colon
      of prebiotic substrates and effects on systemic metabolism and appetite i healthy humans
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose with this project is to study the association between bacterial fermentation in
      the colon of specific mixtures of cereal dietary fiber and effects on systemic metabolism and
      appetite regulation. For this purpose, short term studies are performed in healthy adult
      subjects. Different cereals, cereal blends and from cereal extracted dietary fiber will be
      studied, as well as effects of different processing of the cereals. Cardiometabolic test
      markers and colonic fermentation metabolites will be followed up to 14 h after intake of the
      test substrates, and gut microbiota composition will be determined prior to and after the
      interventions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 10, 2018</start_date>
  <completion_date type="Anticipated">October 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Crossover randomised</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood glucose regulation</measure>
    <time_frame>0-14 h after intake</time_frame>
    <description>Postprandial blood glucose regulation (incremental area under the curve) acute after intake of the test products and at forthcoming meals within 14 h after consumption of test products.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum insulin</measure>
    <time_frame>0-14 h after intake</time_frame>
    <description>Postprandial serum insulin concentrations (incremental area under the curve) acute after intake of the test products and at forthcoming meals within 14 h after consumption of test products.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gut microbiota composition</measure>
    <time_frame>first stool delivered from14 h after intake</time_frame>
    <description>effects on gut microbiota composition after intake of prebiotics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma GLP-1 (glucagon-like peptide-1 ), PYY (peptide tyrosine tyrosine), Ghrelin</measure>
    <time_frame>0-14 h after intake</time_frame>
    <description>Gastro-intestinale hormones involved in appetite and metabolic regulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma: CRP (C reactive protein ), IL (interleukin)-6, IL-18, IL-8, IL-1, IL-10, LBP (lipopolysaccharide-binding protein), (PAI-1plasminogen activator inhibitor)</measure>
    <time_frame>0-14 h after intake</time_frame>
    <description>Inflammatory markers in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma GLP-2</measure>
    <time_frame>0-14 h after intake</time_frame>
    <description>gut hormone involved in gut mucosa integrity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma SCFA (short-chain fatty acid)</measure>
    <time_frame>0-14 h after intake</time_frame>
    <description>colonic fermentation metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood lipids</measure>
    <time_frame>0-14 h after intake</time_frame>
    <description>cholesterol and free fatty acids in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma adiponectin</measure>
    <time_frame>0-14 h after intake</time_frame>
    <description>hormone involved in metabolic regulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma BDNF (Brain-derived neurotrophic factor)</measure>
    <time_frame>0-14 h after intake</time_frame>
    <description>signal protein important for brain functions, but also involved in metabolic regulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma neurotensin</measure>
    <time_frame>0-14 h after intake</time_frame>
    <description>a neuro peptide peptides involved in appetite and metabolic regulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma Nesfatin-1</measure>
    <time_frame>0-14 h after intake</time_frame>
    <description>a neuro peptide that participates in the regulation of hunger and fat storage.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Subjective appetite sensations</measure>
    <time_frame>0-14 h after intake</time_frame>
    <description>determined with VAS (visual analogue scale) scales (0-100 mm)</description>
  </other_outcome>
  <other_outcome>
    <measure>mood (valence and activity)</measure>
    <time_frame>0-14 h after intake</time_frame>
    <description>determined with VAS scales (0-100 mm)</description>
  </other_outcome>
  <other_outcome>
    <measure>Energy intake</measure>
    <time_frame>4 h after intake of a test product or the control product</time_frame>
    <description>ad libitum intake at a second meal after intake of test products</description>
  </other_outcome>
  <other_outcome>
    <measure>breath hydrogen concentrations</measure>
    <time_frame>0-14 h after intake</time_frame>
    <description>indicator of gut fermentation</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Glucose Tolerance</condition>
  <arm_group>
    <arm_group_label>Cereal product 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cereal based muesli made from typical Swedish cereals. All experimental products have different types and amounts of dietary fibre (df).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cereal product 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cereal based muesli made from typical Swedish cereals. All experimental products have different types and amounts of df.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cereal product 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cereal based muesli made from typical Swedish cereals. All experimental products have different types and amounts of df.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cereal product 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cereal based muesli made from typical Swedish cereals. All experimental products have different types and amounts of df.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cereal product 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cereal based muesli made from typical Swedish cereals. All experimental products have different types and amounts of df.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A cereal based product with low concentrations of df.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cereals, dietary fibre</intervention_name>
    <description>Cereal products based on rye, barley, wheat, oat, and corn</description>
    <arm_group_label>Cereal product 1</arm_group_label>
    <arm_group_label>Cereal product 2</arm_group_label>
    <arm_group_label>Cereal product 3</arm_group_label>
    <arm_group_label>Cereal product 4</arm_group_label>
    <arm_group_label>Cereal product 5</arm_group_label>
    <arm_group_label>Control product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy adults

          -  BMI&lt;30

          -  non smokers

          -  consuming a non-vegetarian diet that follows the Nordic guidances

        Exclusion Criteria:

          -  fasting blood glucose &gt;6.1 mmol/L

          -  known cardio-metabolic disease (e.g. diabetes, hypertension, metabolic syndrome),
             gastro-intestinal disorders such as IBS (irritable bowel syndrome) that can interfere
             with the study results, food allergies. Further no antibiotics or probiotics should
             have been consumed within 4 weeks prior to and during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Nilsson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Food Technology, engineering, and Nutrition, LTH, Lund University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Nilsson, PhD</last_name>
    <phone>+46 46 2228342</phone>
    <email>anne.nilsson@food.lth.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Food Technology, engineering and Nutrition, LTH, Lund University</name>
      <address>
        <city>Lund</city>
        <zip>22100</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Granfeldt, Professor</last_name>
      <phone>+46 705 693375</phone>
      <email>yvonne.granfeldt@food.lth.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Nilsson AC, Ã–stman EM, Knudsen KE, Holst JJ, BjÃ¶rck IM. A cereal-based evening meal rich in indigestible carbohydrates increases plasma butyrate the next morning. J Nutr. 2010 Nov;140(11):1932-6. doi: 10.3945/jn.110.123604. Epub 2010 Sep 1.</citation>
    <PMID>20810606</PMID>
  </reference>
  <reference>
    <citation>Nilsson AC, Johansson-Boll EV, BjÃ¶rck IM. Increased gut hormones and insulin sensitivity index following a 3-d intervention with a barley kernel-based product: a randomised cross-over study in healthy middle-aged subjects. Br J Nutr. 2015 Sep 28;114(6):899-907. doi: 10.1017/S0007114515002524. Epub 2015 Aug 11.</citation>
    <PMID>26259632</PMID>
  </reference>
  <reference>
    <citation>Kovatcheva-Datchary P, Nilsson A, Akrami R, Lee YS, De Vadder F, Arora T, Hallen A, Martens E, BjÃ¶rck I, BÃ¤ckhed F. Dietary Fiber-Induced Improvement in Glucose Metabolism Is Associated with Increased Abundance of Prevotella. Cell Metab. 2015 Dec 1;22(6):971-82. doi: 10.1016/j.cmet.2015.10.001. Epub 2015 Nov 6.</citation>
    <PMID>26552345</PMID>
  </reference>
  <reference>
    <citation>Sandberg JC, BjÃ¶rck IM, Nilsson AC. Rye-Based Evening Meals Favorably Affected Glucose Regulation and Appetite Variables at the Following Breakfast; A Randomized Controlled Study in Healthy Subjects. PLoS One. 2016 Mar 18;11(3):e0151985. doi: 10.1371/journal.pone.0151985. eCollection 2016.</citation>
    <PMID>26990559</PMID>
  </reference>
  <reference>
    <citation>Sandberg JC, BjÃ¶rck IME, Nilsson AC. Effects of whole grain rye, with and without resistant starch type 2 supplementation, on glucose tolerance, gut hormones, inflammation and appetite regulation in an 11-14.5 hour perspective; a randomized controlled study in healthy subjects. Nutr J. 2017 Apr 21;16(1):25. doi: 10.1186/s12937-017-0246-5.</citation>
    <PMID>28431559</PMID>
  </reference>
  <reference>
    <citation>Nilsson AC, Ostman EM, Holst JJ, BjÃ¶rck IM. Including indigestible carbohydrates in the evening meal of healthy subjects improves glucose tolerance, lowers inflammatory markers, and increases satiety after a subsequent standardized breakfast. J Nutr. 2008 Apr;138(4):732-9.</citation>
    <PMID>18356328</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2017</study_first_submitted>
  <study_first_submitted_qc>January 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lund University</investigator_affiliation>
    <investigator_full_name>Anne Nilsson</investigator_full_name>
    <investigator_title>Associate professor, PhD</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

